drugset / Trial / NCT05484375
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
Phase 2
Not yet recruiting
40 enrolled
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Hunan Cancer Hospital · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.
Timeline
- Start
- 2022-09
- Primary completion
- 2027-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |